Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma

  1. Sesques, Pierre
  2. Kirkwood, Amy A.
  3. Kwon, Mi
  4. Rejeski, Kai
  5. Jain, Michael D.
  6. Di Blasi, Roberta
  7. Brisou, Gabriel
  8. Gros, François-Xavier
  9. le Bras, Fabien
  10. Bories, Pierre
  11. Choquet, Sylvain
  12. Rubio, Marie-Thérèse
  13. Iacoboni, Gloria
  14. O’Reilly, Maeve
  15. Casasnovas, René-Olivier
  16. Bay, Jacques-Olivier
  17. Mohty, Mohamad
  18. Joris, Magalie
  19. Abraham, Julie
  20. Castilla Llorente, Cristina
  21. Loschi, Mickael
  22. Carras, Sylvain
  23. Chauchet, Adrien
  24. La Rochelle, Laurianne Drieu
  25. Hermine, Olivier
  26. Guidez, Stéphanie
  27. Cony-Makhoul, Pascale
  28. Fogarty, Patrick
  29. Le Gouill, Steven
  30. Morschhauser, Franck
  31. Gastinne, Thomas
  32. Cartron, Guillaume
  33. Subklewe, Marion
  34. Locke, Frederick L.
  35. Sanderson, Robin
  36. Barba, Pere
  37. Houot, Roch
  38. Bachy, Emmanuel

Download
13045_2024_Article_1579.pdf 956,18KB
WeightNameValue
1000 Titel
  • Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
1000 Autor/in
  1. Sesques, Pierre |
  2. Kirkwood, Amy A. |
  3. Kwon, Mi |
  4. Rejeski, Kai |
  5. Jain, Michael D. |
  6. Di Blasi, Roberta |
  7. Brisou, Gabriel |
  8. Gros, François-Xavier |
  9. le Bras, Fabien |
  10. Bories, Pierre |
  11. Choquet, Sylvain |
  12. Rubio, Marie-Thérèse |
  13. Iacoboni, Gloria |
  14. O’Reilly, Maeve |
  15. Casasnovas, René-Olivier |
  16. Bay, Jacques-Olivier |
  17. Mohty, Mohamad |
  18. Joris, Magalie |
  19. Abraham, Julie |
  20. Castilla Llorente, Cristina |
  21. Loschi, Mickael |
  22. Carras, Sylvain |
  23. Chauchet, Adrien |
  24. La Rochelle, Laurianne Drieu |
  25. Hermine, Olivier |
  26. Guidez, Stéphanie |
  27. Cony-Makhoul, Pascale |
  28. Fogarty, Patrick |
  29. Le Gouill, Steven |
  30. Morschhauser, Franck |
  31. Gastinne, Thomas |
  32. Cartron, Guillaume |
  33. Subklewe, Marion |
  34. Locke, Frederick L. |
  35. Sanderson, Robin |
  36. Barba, Pere |
  37. Houot, Roch |
  38. Bachy, Emmanuel |
1000 Verlag BioMed Central
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-08-06
1000 Erschienen in
1000 Quellenangabe
  • 17(1):61
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s13045-024-01579-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11305039/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Autologous anti-CD19 chimeric antigen receptor (CAR) T cells are now used in routine practice for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Severe (grade ≥ 3) cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) are still the most concerning acute toxicities leading to frequent intensive care unit (ICU) admission, prolonging hospitalization, and adding significant cost to treatment. We report on the incidence of CRS and ICANS and the outcomes in a large cohort of 925 patients with LBCL treated with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) in France based on patient data captured through the DESCAR-T registry. CRS of any grade occurred in 778 patients (84.1%), with 74 patients (8.0%) with grade 3 CRS or higher, while ICANS of any grade occurred in 375 patients (40.5%), with 112 patients (12.1%) with grade ≥ 3 ICANS. Based on the parameters selected by multivariable analyses, two independent prognostic scoring systems (PSS) were derived, one for grade ≥ 3 CRS and one for grade ≥ 3 ICANS. CRS-PSS included bulky disease, a platelet count &lt; 150 G/L, a C-reactive protein (CRP) level &gt; 30 mg/L and no bridging therapy or stable or progressive disease (SD/PD) after bridging. Patients with a CRS-PSS score &gt; 2 had significantly higher risk to develop grade ≥ 3 CRS. ICANS-PSS included female sex, low level of platelets (&lt; 150 G/L), use of axi-cel and no bridging therapy or SD/PD after bridging. Patients with a CRS-PSS score &gt; 2 had significantly higher risk to develop grade ≥ 3 ICANS. Both scores were externally validated in international cohorts of patients treated with tisa-cel or axi-cel.</jats:p>
1000 Sacherschließung
lokal Biological Products/therapeutic use [MeSH]
lokal Female [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Immunotherapy, Adoptive/adverse effects [MeSH]
lokal Neurotoxicity Syndromes/etiology [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Middle Aged [MeSH]
lokal France [MeSH]
lokal Antigens, CD19/immunology [MeSH]
lokal Lymphoma, Large B-Cell, Diffuse/immunology [MeSH]
lokal Lymphoma, Large B-Cell, Diffuse/therapy [MeSH]
lokal Male [MeSH]
lokal Cytokine Release Syndrome/etiology [MeSH]
lokal Research
lokal Biological Products/adverse effects [MeSH]
lokal Prognosis [MeSH]
lokal Receptors, Antigen, T-Cell [MeSH]
lokal Immunotherapy, Adoptive/methods [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/U2VzcXVlcywgUGllcnJl|https://frl.publisso.de/adhoc/uri/S2lya3dvb2QsIEFteSBBLg==|https://frl.publisso.de/adhoc/uri/S3dvbiwgTWk=|https://frl.publisso.de/adhoc/uri/UmVqZXNraSwgS2Fp|https://frl.publisso.de/adhoc/uri/SmFpbiwgTWljaGFlbCBELg==|https://frl.publisso.de/adhoc/uri/RGkgQmxhc2ksIFJvYmVydGE=|https://frl.publisso.de/adhoc/uri/QnJpc291LCBHYWJyaWVs|https://frl.publisso.de/adhoc/uri/R3JvcywgRnJhbsOnb2lzLVhhdmllcg==|https://frl.publisso.de/adhoc/uri/bGUgQnJhcywgRmFiaWVu|https://frl.publisso.de/adhoc/uri/Qm9yaWVzLCBQaWVycmU=|https://frl.publisso.de/adhoc/uri/Q2hvcXVldCwgU3lsdmFpbg==|https://frl.publisso.de/adhoc/uri/UnViaW8sIE1hcmllLVRow6lyw6hzZQ==|https://frl.publisso.de/adhoc/uri/SWFjb2JvbmksIEdsb3JpYQ==|https://frl.publisso.de/adhoc/uri/T_KAmVJlaWxseSwgTWFldmU=|https://frl.publisso.de/adhoc/uri/Q2FzYXNub3ZhcywgUmVuw6ktT2xpdmllcg==|https://frl.publisso.de/adhoc/uri/QmF5LCBKYWNxdWVzLU9saXZpZXI=|https://frl.publisso.de/adhoc/uri/TW9odHksIE1vaGFtYWQ=|https://frl.publisso.de/adhoc/uri/Sm9yaXMsIE1hZ2FsaWU=|https://frl.publisso.de/adhoc/uri/QWJyYWhhbSwgSnVsaWU=|https://frl.publisso.de/adhoc/uri/Q2FzdGlsbGEgTGxvcmVudGUsIENyaXN0aW5h|https://frl.publisso.de/adhoc/uri/TG9zY2hpLCBNaWNrYWVs|https://frl.publisso.de/adhoc/uri/Q2FycmFzLCBTeWx2YWlu|https://frl.publisso.de/adhoc/uri/Q2hhdWNoZXQsIEFkcmllbg==|https://frl.publisso.de/adhoc/uri/TGEgUm9jaGVsbGUsIExhdXJpYW5uZSBEcmlldQ==|https://frl.publisso.de/adhoc/uri/SGVybWluZSwgT2xpdmllcg==|https://frl.publisso.de/adhoc/uri/R3VpZGV6LCBTdMOpcGhhbmll|https://frl.publisso.de/adhoc/uri/Q29ueS1NYWtob3VsLCBQYXNjYWxl|https://frl.publisso.de/adhoc/uri/Rm9nYXJ0eSwgUGF0cmljaw==|https://frl.publisso.de/adhoc/uri/TGUgR291aWxsLCBTdGV2ZW4=|https://frl.publisso.de/adhoc/uri/TW9yc2NoaGF1c2VyLCBGcmFuY2s=|https://frl.publisso.de/adhoc/uri/R2FzdGlubmUsIFRob21hcw==|https://frl.publisso.de/adhoc/uri/Q2FydHJvbiwgR3VpbGxhdW1l|https://frl.publisso.de/adhoc/uri/U3Via2xld2UsIE1hcmlvbg==|https://frl.publisso.de/adhoc/uri/TG9ja2UsIEZyZWRlcmljayBMLg==|https://frl.publisso.de/adhoc/uri/U2FuZGVyc29uLCBSb2Jpbg==|https://frl.publisso.de/adhoc/uri/QmFyYmEsIFBlcmU=|https://frl.publisso.de/adhoc/uri/SG91b3QsIFJvY2g=|https://frl.publisso.de/adhoc/uri/QmFjaHksIEVtbWFudWVs
1000 Hinweis
  • DeepGreen-ID: 9e8de77bc74e488d80eb7bb0096873ca ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6508604.rdf
1000 Erstellt am 2025-02-06T17:51:51.573+0100
1000 Erstellt von 322
1000 beschreibt frl:6508604
1000 Zuletzt bearbeitet 2025-09-14T06:57:27.325+0200
1000 Objekt bearb. Sun Sep 14 06:57:27 CEST 2025
1000 Vgl. frl:6508604
1000 Oai Id
  1. oai:frl.publisso.de:frl:6508604 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source